GO curators for mouse genes have assigned the following annotations to the gene product of Btk. (This text reflects annotations as of Wednesday, January 23, 2013.) Summary from NCBI RefSeq
[Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008]Summary text based on GO annotations supported by experimental evidence in mouse
Researchers have inferred from direct assay, that the gene product of Btk
participates in the following biological processes:
Antony P et al. (2003) B cell receptor directs the activation of NFAT and NF-kappaB via distinct molecular mechanisms. Exp Cell Res, 291:11-24. (PubMed:14597404)
Clayton E et al. (2002) A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med, 196:753-63. (PubMed:12235209)
Iseki M et al. (2000) Molecular cloning of the mouse APS as a member of the Lnk family adaptor proteins. Biochem Biophys Res Commun, 272:45-54. (PubMed:10872802)
Kikuchi Y et al. (2000) Identification and characterization of a molecule, BAM11, that associates with the pleckstrin homology domain of mouse Btk Int Immunol, 12:1397-408. (PubMed:11007757)
Kraemer FB et al. (2004) Hormone-sensitive lipase is required for high-density lipoprotein cholesteryl ester-supported adrenal steroidogenesis. Mol Endocrinol, 18:549-57. (PubMed:14657254)
Liu X et al. (2011) Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol, 12:416-24. (PubMed:21441935)
Middendorp S et al. (2004) Cellular maturation defects in Bruton's tyrosine kinase-deficient immature B cells are amplified by premature B cell receptor expression and reduced by receptor editing. J Immunol, 172:1371-9. (PubMed:14734712)
Nixon JC et al. (2004) Mutations in the DNA-binding domain of the transcription factor Bright act as dominant negative proteins and interfere with immunoglobulin transactivation. J Biol Chem, 279:52465-72. (PubMed:15456761)